Literature DB >> 26419448

Rho Kinases in Health and Disease: From Basic Science to Translational Research.

Gervaise Loirand1.   

Abstract

Rho-associated kinases ROCK1 and ROCK2 are key regulators of actin cytoskeleton dynamics downstream of Rho GTPases that participate in the control of important physiologic functions, S including cell contraction, migration, proliferation, adhesion, and inflammation. Several excellent review articles dealing with ROCK function and regulation have been published over the past few years. Although a brief overview of general molecular, biochemical, and functional properties of ROCKs is included, an effort has been made to produce an original work by collecting and synthesizing recent studies aimed at translating basic discoveries from cell and experimental models into knowledge of human physiology, pathophysiological mechanisms, and medical therapeutics. This review points out the specificity and distinct roles of ROCK1 and ROCK2 isoforms highlighted in the last few years. Results obtained from genetically modified mice and genetic analysis in humans are discussed. This review also addresses the involvement of ROCKs in human diseases and the potential use of ROCK activity as a biomarker or a pharmacological target for specific inhibitors.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26419448     DOI: 10.1124/pr.115.010595

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  58 in total

1.  Heterogeneous Impact of ROCK2 on Carotid and Cerebrovascular Function.

Authors:  T Michael De Silva; Dale A Kinzenbaw; Mary L Modrick; Lindsey D Reinhardt; Frank M Faraci
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

2.  A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease.

Authors:  Lisa McKerracher; Robert Shenkar; Matthew Abbinanti; Ying Cao; Amy Peiper; James K Liao; Rhonda Lightle; Thomas Moore; Nicholas Hobson; Carol Gallione; Joerg Ruschel; Janne Koskimäki; Romuald Girard; Kenneth Rosen; Douglas A Marchuk; Issam A Awad
Journal:  Transl Stroke Res       Date:  2019-08-24       Impact factor: 6.829

3.  ROCK1-PredictedmicroRNAs Dysregulation Contributes to Tumor Progression in Ewing Sarcoma.

Authors:  G M Roberto; L E A Delsin; G M Vieira; M O Silva; R G Hakime; N F Gava; E E Engel; C A Scrideli; L G Tone; María Sol Brassesco
Journal:  Pathol Oncol Res       Date:  2017-12-21       Impact factor: 3.201

Review 4.  Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.

Authors:  Megumi Honjo; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

Review 5.  T cells and autoimmune kidney disease.

Authors:  Abel Suárez-Fueyo; Sean J Bradley; David Klatzmann; George C Tsokos
Journal:  Nat Rev Nephrol       Date:  2017-03-13       Impact factor: 28.314

Review 6.  Contribution of Rho-kinase and Adenosine Monophosphate-Activated Protein Kinase Signaling Pathways to Endothelium-Derived Contracting Factors Responses.

Authors:  Cennet Balcilar; Işıl Özakça; Vecdi Melih Altan
Journal:  Turk J Pharm Sci       Date:  2017-08-15

Review 7.  Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.

Authors:  Ponugoti Vasantha Rao; Padmanabhan P Pattabiraman; Casey Kopczynski
Journal:  Exp Eye Res       Date:  2016-09-01       Impact factor: 3.467

8.  Central Angiotensin-II Increases Blood Pressure and Sympathetic Outflow via Rho Kinase Activation in Conscious Rabbits.

Authors:  Peter R Pellegrino; Alicia M Schiller; Karla K V Haack; Irving H Zucker
Journal:  Hypertension       Date:  2016-09-26       Impact factor: 10.190

9.  Enhanced KCl-mediated contractility and Ca2+ sensitization in porcine collateral-dependent coronary arteries persist after exercise training.

Authors:  Cristine L Heaps; Jeff F Bray; Janet L Parker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-08-28       Impact factor: 4.733

Review 10.  Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

Authors:  Angelo P Tanna; Mark Johnson
Journal:  Ophthalmology       Date:  2018-07-12       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.